Liangrunbio Biomedical Technology Co., Ltd.

Product development focusing on early detection and surveillance in the fields of tumors, neurodegenerative diseases, and infectious diseases

Liangrunbio Biomedical Technology Co., Ltd. (hereinafter referred to as "Shanghai Liangrun") was established in 2013 with a registered capital of 104 million yuan. The company is located in the Shanghai Free Trade Pilot Zone. It is a national high-tech enterprise focusing on the independent research and development and industrialized production of innovative reagents and key raw materials for early screening and early diagnosis of major diseases such as tumors, neurodegenerative diseases, and infectious diseases. It is a "specialized, refined and new" enterprise in Shanghai, the first batch of "Global Operator Program (GOP)" enterprises in Shanghai Free Trade Zone, and won the title of "Patent Work Pilot" in Shanghai and Pudong New Area.

  • 2013

    Founded In

  • 32


  • Driven by technological innovation

    Liangrunbio has always adhered to "technological innovation", relying on the discovery and verification of innovative protein biomarkers, especially exosome protein detection technology, and focusing on the development strategy of new immune products. It has applied for 32 independent innovation patent technologies, of which 17 have been authorized for invention patents. The company independently developed the world's first new marker of gastrointestinal cancer, CST4 kit (Elisa method), NMPA has been approved three types of registration certificate (National Instrument 20173403280) and CE certification; new lung cancer monitoring marker FXYD (chemiluminescence method) has been completed Clinical trials are about to apply for NMPA review; the new crown IgG/IgM kit (colloidal gold) has completed clinical trials and plans to apply for NMPA registration review; at the same time, it has also achieved independent research and development on key raw materials such as antigens and antibodies. The company has an independent scientific research laboratory of 800 square meters and a GMP standard modern workshop of 2000 square meters. It can produce more than 250 million people per year for the industrialization of diagnostic reagents, and has passed the international ISO13485 quality system certification. In the next 2-3 years, it is expected that 3-5 international or domestic products will be launched one after another.
  • COVID-19 fight

    In 2020, Liangrunbio actively participated in the construction of public health undertakings and played an important role in the fight against the new crown epidemic at home and abroad.

    Liangrun people are focusing on "seeing what others haven't seen and doing what others haven't done" with the spirit of "honest innovation and outstanding responsibility", and will show their skills in the situation and strive to be the "true" of the times. hero"!

    Hotline: 021-50680557

    Address: 5th Floor, Building 2, No. 271, Gangao Road,
    Shanghai Pilot Free Trade Zone, China